CUSTOMIZED BRIGHTFIELD MULTIPLEX IHC
This customizable solution, a sequential brightfield chromogenic multiplex IHC, in addition to whole slide digital pathology analysis, allows researchers to assess complex TME cells phenotyping from one FFPE tumor tissue section with up-to 7 biomarkers; providing valuable predictive and prognostic information, as well as insights on the underlying mechanisms of therapy response and resistance.
Our expertise in immuno-oncology combined with our IO Biomarkers Experts and scientists ensures rapid development of your priority projects and provides dedicated support during all steps of development.
Veracyte has strong expertise in complex panel development, containing up-to 7 biomarkers each, for the identification of complex cell phenotypes.
Our image and data analysis ensures a standardized quantification of cell populations and the assessment of cells clustering, as well as a proximity index.
Cancer Immunogram: combining multi-parameter approach and machine learning to capture the complexity of tumor immune contexture. (SITC 2019)
Immunoscore® for Clinical Research (CR)
Leverage Veracyte know-how acquired with Immunoscore®, to propose an enhanced next generation Immunoscore® with multiplex and spatially resolved capabilities for clinical investigations.
- Robust immunohistochemistry assays using standardized reagents
- Classify tumors as hot/cold, exhausted/not exhausted and immunosuppressed/not immunosuppressed
- Flexible multiplexing capabilities
- Deliver spatially resolved phenotypic imaging data
- Validated in several cancer types
